{
  "id": 19449913,
  "title": "Morgan Stanley downgrades Halozyme stock rating on valuation",
  "url": "https://urgent.news/2026/11/11/morgan-stanley-downgrades-halozyme-stock-rating-on-valuation",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-11T05:08:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/morgan-stanley-downgrades-halozyme-stock-rating-on-valuation-93CH-5017702"
  },
  "original_language": "en",
  "account": "Morgan Stanley has lowered its rating on Halozyme Therapeutics (NASDAQ: HALO) stock, downgrading it from Overweight to Equalweight and increasing the price target to $109 from $105. The analyst, Sean Laaman, explained that Halozyme's royalty base is becoming more diversified, and its European intellectual property position has strengthened significantly in October.\n\nThe $109 valuation is based on the current royalty portfolio, with peak values expected in 2029 due to scheduled royalty-rate step-downs. The firm believes that Halozyme's growth can continue beyond these step-downs through Hypercon, a new antibody-drug conjugate opportunity and upcoming ENHANZE launches. Morgan Stanley plans to incorporate these prospects more fully into their valuation as Hypercon progresses through clinical trials and antibody-drug conjugates gain proof of concept.\n\nHalozyme's shares have increased by 53% year-to-date, outperforming the Nasdaq Biotechnology Index's 31% gain. Despite a recent 21% drop over the past week, the stock is currently trading close to Morgan Stanley's base case value. Halozyme maintains a strong free cash flow yield of 8% and a high financial health score. For investors seeking further insight, the company provides a comprehensive Pro Research Report on HALO, one of more than 1,400 available for US equities.",
  "summary": null,
  "key_points": [
    "Morgan Stanley downgrades Halozyme stock rating to Equalweight",
    "Price target raised to $109 from $105",
    "Analyst cites diversified royalty base and strengthened European IP"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}